Progress on Securing Nuclear Weapons and Materials: The Four-Year Effort and Beyond

On the eve of the Nuclear Security Summit in Seoul, South Korea, a new study finds that an international initiative to secure all vulnerable nuclear stockpiles within four years has reduced the dangers they pose. But the new analysis, by researchers in Harvard University’s Project on Managing the Atom, also concludes that much will remain to be done to ensure that all nuclear weapons and material are secure when the current four-year effort comes to an end. “At the end of four years, the global risks of nuclear theft will be significantly lower than they were before,” said co-author Matthew Bunn, associate professor of public policy at Harvard Kennedy School. “But there will still be a great deal left to do to make sure that all the world’s stocks of nuclear weapons and the materials needed to make them are protected from the full range of plausible terrorist and criminal threats – in a way that will last.” The other co-authors of the report are Martin B. Malin, executive director of the Project on Managing the Atom in the Kennedy School’s Belfer Center for Science and International Affairs, and Eben Harrell, research associate in the Managing the Atom project. The study, “Progress on Securing Nuclear Weapons and Materials: the Four-Year Effort and Beyond,” was released in advance of the Seoul summit on March 26-27, 2012, being attended by leaders or senior officials from 54 countries and four international organizations

Advancing Nuclear Security:Evaluating Progress and Setting New Goals

The threat of nuclear and radiological terrorism has not disappeared, though the world has made important progress in reducing these risks. Urgent new steps are needed to build effective and lasting nuclear security worldwide. The nuclear security effort must now shift from short-term improvements toward a focus on a continued search for excellence, lasting as long as terrorist groups bent on mass destruction and the nuclear and radiological materials they might use both continue to exist

Cool Farm Tool Water : A global on-line tool to assess water use in crop production

© 2018 The Authors.Peer reviewedPublisher PD

CFHTLenS tomographic weak lensing: Quantifying accurate redshift distributions

The Canada-France-Hawaii Telescope Lensing Survey (CFHTLenS) comprises deep multi-colour (u*g'r'i'z') photometry spanning 154 square degrees, with accurate photometric redshifts and shape measurements. We demonstrate that the redshift probability distribution function summed over galaxies provides an accurate representation of the galaxy redshift distribution accounting for random and catastrophic errors for galaxies with best fitting photometric redshifts z_p < 1.3. We present cosmological constraints using tomographic weak gravitational lensing by large-scale structure. We use two broad redshift bins 0.5 < z_p <= 0.85 and 0.85 < z_p <= 1.3 free of intrinsic alignment contamination, and measure the shear correlation function on angular scales in the range ~1-40 arcmin. We show that the problematic redshift scaling of the shear signal, found in previous CFHTLS data analyses, does not afflict the CFHTLenS data. For a flat Lambda-CDM model and a fixed matter density Omega_m=0.27, we find the normalisation of the matter power spectrum sigma_8=0.771 \pm 0.041. When combined with cosmic microwave background data (WMAP7), baryon acoustic oscillation data (BOSS), and a prior on the Hubble constant from the HST distance ladder, we find that CFHTLenS improves the precision of the fully marginalised parameter estimates by an average factor of 1.5-2. Combining our results with the above cosmological probes, we find Omega_m=0.2762 \pm 0.0074 and sigma_8=0.802 \pm 0.013.Comment: 17 pages, 12 figures, submitted to MNRA

CFHTLenS: combined probe cosmological model comparison using 2D weak gravitational lensing

We present cosmological constraints from 2D weak gravitational lensing by the large-scale structure in the Canada–France–Hawaii Telescope Lensing Survey (CFHTLenS) which spans 154 deg^2 in five optical bands. Using accurate photometric redshifts and measured shapes for 4.2 million galaxies between redshifts of 0.2 and 1.3, we compute the 2D cosmic shear correlation function over angular scales ranging between 0.8 and 350 arcmin. Using non-linear models of the dark-matter power spectrum, we constrain cosmological parameters by exploring the parameter space with Population Monte Carlo sampling. The best constraints from lensing alone are obtained for the small-scale density-fluctuations amplitude σ_8 scaled with the total matter density Ωm. For a flat Λcold dark matter (ΛCDM) model we obtain σ_8(Ω_m/0.27)0.6 = 0.79 ± 0.03. We combine the CFHTLenS data with 7-year Wilkinson Microwave Anisotropy Probe (WMAP7), baryonic acoustic oscillations (BAO): SDSS-III (BOSS) and a Hubble Space Telescope distance-ladder prior on the Hubble constant to get joint constraints. For a flat ΛCDM model, we find Ω_m = 0.283 ± 0.010 and σ_8 = 0.813 ± 0.014. In the case of a curved wCDM universe, we obtain Ω_m = 0.27 ± 0.03, σ_8 = 0.83 ± 0.04, w0 = −1.10 ± 0.15 and Ω_K = 0.006^(+0.006)_(− 0.004). We calculate the Bayesian evidence to compare flat and curved ΛCDM and dark-energy CDM models. From the combination of all four probes, we find models with curvature to be at moderately disfavoured with respect to the flat case. A simple dark-energy model is indistinguishable from ΛCDM. Our results therefore do not necessitate any deviations from the standard cosmological model

Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS

BackgroundUpon treatment with biopharmaceuticals, the immune system may produce anti-drug antibodies (ADA) that inhibit the therapy. Up to 40% of multiple sclerosis patients treated with interferon beta (IFN beta) develop ADA, for which a genetic predisposition exists. Here, we present a genome-wide association study on ADA and predict the occurrence of antibodies in multiple sclerosis patients treated with different interferon beta preparations.MethodsWe analyzed a large sample of 2757 genotyped and imputed patients from two cohorts (Sweden and Germany), split between a discovery and a replication dataset. Binding ADA (bADA) levels were measured by capture-ELISA, neutralizing ADA (nADA) titers using a bioassay. Genome-wide association analyses were conducted stratified by cohort and treatment preparation, followed by fixed-effects meta-analysis.ResultsBinding ADA levels and nADA titers were correlated and showed a significant heritability (47% and 50%, respectively). The risk factors differed strongly by treatment preparation: The top-associated and replicated variants for nADA presence were the HLA-associated variants rs77278603 in IFN beta -1a s.c.- (odds ratio (OR)=3.55 (95% confidence interval=2.81-4.48), p=2.1x10(-26)) and rs28366299 in IFN beta -1b s.c.-treated patients (OR=3.56 (2.69-4.72), p=6.6x10(-19)). The rs77278603-correlated HLA haplotype DR15-DQ6 conferred risk specifically for IFN beta -1a s.c. (OR=2.88 (2.29-3.61), p=7.4x10(-20)) while DR3-DQ2 was protective (OR=0.37 (0.27-0.52), p=3.7x10(-09)). The haplotype DR4-DQ3 was the major risk haplotype for IFN beta -1b s.c. (OR=7.35 (4.33-12.47), p=1.5x10(-13)). These haplotypes exhibit large population-specific frequency differences. The best prediction models were achieved for ADA in IFN beta -1a s.c.-treated patients. Here, the prediction in the Swedish cohort showed AUC=0.91 (0.85-0.95), sensitivity=0.78, and specificity=0.90;patients with the top 30% of genetic risk had, compared to patients in the bottom 30%, an OR =73.9 (11.8-463.6, p=4.4x10(-6)) of developing nADA. In the German cohort, the AUC of the same model was 0.83 (0.71-0.92), sensitivity=0.80, specificity=0.76, with an OR=13.8 (3.0-63.3, p=7.5x10(-4)).ConclusionsWe identified several HLA-associated genetic risk factors for ADA against interferon beta, which were specific for treatment preparations and population backgrounds. Genetic prediction models could robustly identify patients at risk for developing ADA and might be used for personalized therapy recommendations and stratified ADA screening in clinical practice. These analyses serve as a roadmap for genetic characterizations of ADA against other biopharmaceutical compounds

DNA barcode reference libraries for the monitoring of aquatic biota in Europe: Gap-analysis and recommendations for future work

Effective identification of species using short DNA fragments (DNA barcoding and DNA metabarcoding) requires reliable sequence reference libraries of known taxa. Both taxonomically comprehensive coverage and content quality are important for sufficient accuracy. For aquatic ecosystems in Europe, reliable barcode reference libraries are particularly important if molecular identification tools are to be implemented in biomonitoring and reports in the context of the EU Water Framework Directive (WFD) and the Marine Strategy Framework Directive (MSFD). We analysed gaps in the two most important reference databases, Barcode of Life Data Systems (BOLD) and NCBI GenBank, with a focus on the taxa most frequently used in WFD and MSFD. Our analyses show that coverage varies strongly among taxonomic groups, and among geographic regions. In general, groups that were actively targeted in barcode projects (e.g. fish, true bugs, caddisflies and vascular plants) are well represented in the barcode libraries, while others have fewer records (e.g. marine molluscs, ascidians, and freshwater diatoms). We also found that species monitored in several countries often are represented by barcodes in reference libraries, while species monitored in a single country frequently lack sequence records. A large proportion of species (up to 50%) in several taxonomic groups are only represented by private data in BOLD. Our results have implications for the future strategy to fill existing gaps in barcode libraries, especially if DNA metabarcoding is to be used in the monitoring of European aquatic biota under the WFD and MSFD. For example, missing species relevant to monitoring in multiple countries should be prioritized for future collaborative programs. We also discuss why a strategy for quality control and quality assurance of barcode reference libraries is needed and recommend future steps to ensure full utilisation of metabarcoding in aquatic biomonitoring.This paper is a deliverable of the European Cooperation in Science and Technology (COST) Action DNAqua-Net (CA15219) Working Group 1, led by Torbjørn Ekrem and Fedor Čiampor. Thanks to the University of Minho and University of Pécs for hosting workshops and working group meetings. We also thank staff at National Environment Agencies and others that provided national checklists of taxa used in biomonitoring, and otherwise assisted with checklist proof-reading: Jarmila Makovinská and Emília Mišíková Elexová (Slovakia); Steinar Sandøy and Dag Rosland (Norway); Mišel Jelič (Croatia); Marlen Vasquez (Cyprus); Adam Petrusek (Czech Republic); Kristel Panksep (Estonia); Panagiotis Kaspiditis (Greece); Matteo Montagna (Italy); Marija Katarzyte (Lithuania); Ana Rotter (Slovenia); Rosa Trabajo (Spain); Florian Altermatt (Switzerland); Kristian Meissner (Finland), Rigers Bakiu (Albania), Valentina Stamenkovic and Jelena Hinic (Macedonia); Patricia Mergen (Belgium); Gael Denys & the French Biodiversity Agency (France); Mary Kelly-Quinn (Ireland); Piotr Panek and Andrzej Zawal (Poland); Cesare Mario Puzzi (Italy); Carole Fitzpatrick (United Kingdom); Simon Vitecek (Austria); Ana Filipa Filipe (Portugal); Peter Anton Stæhr & Anne Winding (Denmark); Michael Monaghan (Germany); Alain Dohet, Lionel L'Hoste, Nora Welschbillig & Luc Ector (Luxembourg), Lujza Keresztes, (Romania). The authors also want to thank Dirk Steinke for providing the original European ERMS list for marine taxa and Florian Malard for comments on the manuscript. The preparation of the AMBI checklist was carried out in the scope of a Short-term Scientific Mission (ECOST-STSM-CA15219-150217- 082111) granted to SD visiting AZTI, Spain. ZC was supported by grants EFOP-3.6.1.-16-2016-00004 and 20765-3/2018/FEKUTSTRAT. TE was supported by the NorBOL-grant (226134/F50) from the Research Coun cil of Norway. BR, FL and MFG contributed through support from the GBOL project, which is generously funded by the German Federal Min istry of Education and Research (FKZ 01LI1101 and 01LI1501). MG contributed through support of the Polish National Science Centre, grants N N303 5794 39 and 2014/15/B/NZ8/00266. SF was funded by the project PORBIOTA - Portuguese E-Infrastructure for Information and Research on Biodiversity (POCI-01-0145-FEDER-022127), supported by Operational Thematic Program for Competitiveness and Internationalization (POCI), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (FEDER)

Fifth European Dirofilaria and Angiostrongylus Days (FiEDAD) 2016

Peer reviewe

Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

Funder: Funder: Fundación bancaria ‘La Caixa’ Number: LCF/PR/PR16/51110003 Funder: Grifols SA Number: LCF/PR/PR16/51110003 Funder: European Union/EFPIA Innovative Medicines Initiative Joint Number: 115975 Funder: JPco-fuND FP-829-029 Number: 733051061Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer's disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer's disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer's disease